BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  FDA

  FDA Makes Changes to Alzheimer’s Clinical Trial Goals Amidst Recent Failures

  Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.

  February 19, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Analysts Split Over Buffett’s Backing of Teva Pharma

  Some analysts are scratching their head over Warren Buffet’s investment in Teva Pharma.

  February 19, 2018

   · 

  2 min read

   · 

  Alex Keown
• 3 Top Biotech Stocks to Consider in February

  Analysts with The Motley Fool looked at three biotech stocks that even biotech-leery investors might consider.

  February 19, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  3 Biotech Stocks That Soared Recently

  Three biotech stocks gained over 25 percent last week.

  February 19, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Eli Lilly and Hanmi Shutter a Failed Phase II RA Trial

  Eli Lilly and its Korean collaborative partner Hanmi stopped a Phase II trial on an experimental rheumatoid arthritis treatment following less-than-stellar interim results.

  February 19, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Novartis Could Put Sandoz U.S. Generic Pills Business on the Auction Block Within a Few Weeks

  Novartis may soon be looking to sell off its generics subsidiary Sandoz.

  February 19, 2018

   · 

  2 min read

   · 

  Alex Keown
• Drug Development

  AAD 2018: Treatment with Lilly’s Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

  Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe genital psoriasis treated with Taltz (ixekizumab) reported a greater decrease in the impact of their condition...

  February 19, 2018

   · 

  8 min read
• GenePOC Launches Its revogene™ Instrument and GBS LB Test in Canada

  GenePOC Inc., member of the Debiopharm Group(TM), is proud to announce the launch in its home market for the revogene instrument and the GenePOC(TM) GBS LB assay.

  February 19, 2018

   · 

  2 min read
• EpigenCare is Trying to Disrupt the Skincare Industry

  EpigenCare Inc. has revealed the world’s first project for truly personalized skincare based on epigenetics and blockchain technology

  February 19, 2018

   · 

  4 min read
• Optimal Research and OncoLens™ Collaborate on Just-in-time Clinical Trials for Cancer Patients

  Enabling patients to enroll in trials faster, obtain treatment at local community cancer centers..

  February 19, 2018

   · 

  2 min read